The Evolving Global AI Regulatory Landscape: Recent Developments and Practical Insights for Clinical Trials Webinar Replay
In an era where artificial intelligence (AI) is transforming industries, regulatory bodies worldwide are stepping up to establish frameworks ensuring the safe and ethical application of this groundbreaking technology.
Now available on-demand:
Delve into the recent developments in the global AI regulatory landscape that impact the clinical trial aspect of drug development. This on-demand webinar covers the key elements of the European Union (EU) AI Act, which came into force on August 1, 2024; the US Food and Drug Administration (FDA)’s January 2025 updated draft guidance for the Use of AI to Support Regulatory Decision-Making for Drug and Biologic Products; and other emerging AI regulations across the globe.
Speakers provide an in-depth analysis of the risk principles driving these global regulatory changes and their profound impact on clinical trial workflows and data capture. This includes a strong emphasis on maintaining patient safety, ensuring data accuracy, and enhancing the overall efficiency of clinical development processes.
The webinar also explores Clario’s AI Responsible Use Principles, offering a roadmap for proactively addressing regulatory concerns within clinical trials. It outlines steps to develop, implement, and utilize AI in a manner that is fair, transparent, safe, and ethical.
Watch this on-demand webinar to gain insights into:
- The current global AI regulatory environment, including insights into the EU AI Act, FDA’s recent guidance updates, and emerging global AI regulations.
- Key regulatory concerns in clinical development, focusing on fairness, participant privacy and safety, data accuracy, model transparency, and accountability for AI usage.
- Essential considerations for integrating AI-driven technologies into clinical trial workflows while adhering to current regulations and guidelines.
Access this valuable resource to stay informed and drive innovation in clinical trials through a comprehensive understanding of the evolving AI regulatory landscape.
